pharmaphorum2 天
ASCO22: Enhertu aces key HER2-low test in breast cancer
In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...
pharmaphorum2 天
Seagen wins Enhertu patent dispute with Daiichi Sankyo
A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...